EcoDrugPlus

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSDCDG00000022821
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-2-Like

Ensembl ID : ENSDCDG00000006021
Gene Symbol: LOC114779262
3 Cross references
200 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSDCDG00000004294
Gene Symbol: LOC114798902
3 Cross references
210 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSDCDG00000001654
Gene Symbol: LOC114790190
2 Cross references
241 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta-Like

Ensembl ID : ENSDCDG00000032777
Gene Symbol: LOC114764657
3 Cross references
194 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSDCDG00000013729
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSDCDG00000023354
Gene Symbol: REN
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSDCDG00000029480
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A-Like

Ensembl ID : ENSDCDG00000003462
Gene Symbol: LOC114799196
3 Cross references
223 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSDCDG00000008486
Gene Symbol: LOC114790085
3 Cross references
215 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSDCDG00000031332
Gene Symbol: RARB
3 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Gamma-A

Ensembl ID : ENSDCDG00000004066
Gene Symbol: LOC114798558
3 Cross references
326 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).